The Analysis of Immunohistochemistry Staining, Neuronspecific Enolase (NSE) Level and Somatostatin Receptor Scintigraphy of Gastroenteropancreatic Neuroendocrine Neoplasm Cases Abstract #873

Introduction: 99mTc-HYNIC-TYR3-OCTREOTIDE somatostatin receptor (SSR) scintigraphy has been used to diagnose gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN).
Aim(s): To evaluate the value of neuroendocrine biomarkers in the diagnosis of GEP-NEN and the relationship between 99mTc-HYNIC-TYR3-OCTREOTIDE SSR scintigraphy and tumor differentiation.
Materials and methods: Seventy-seven GEP-NEN patients were included. The neuroendocrine properties of the tumors were determined by IHC of Syn and CgA.Plasma neuronspecific enolase (NSE) levels were measured, and all the patients had 99mTc-HYNIC-TYR3-OCTREOTIDE somatostatin receptor scintigraphy results.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, Li J, Yang Z

To read results and conclusion, please login ...

Further abstracts you may be interested in

#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...
#1051 An Intrapatient Comparison of 99mTc-HYNIC-TOC with 68Ga-DOTA-TATE for Imaging Abilities of Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Imaging with 68Ga-labled somatostatin analogs provides some advantages over SRS imaging, and has therefore recently become more poprlar.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Yu Jiangyuan
Authors: Yu J, Li J, Yang Z, ...
#1171 Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors
Introduction: According to 2010 WHO grading system, all neuroendocrine neoplasms were divided into G1/G2/G3 based on Ki-67 and mitotic count. However, differentiation was also very important for the biological behavior and treatment strategy.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Ru Jia
Authors: Jia R, Chen H E, Chen Y L, Ge F J, ...
#1304 Analysis of 18FDG-PET/CT in Patients with Gastrointestinal Neuroendocrine Neoplasm
Introduction: Gastrointestinal neuroendocrine neoplasm (Gi-NEN) comprised a wide and heterogeneous group of neoplasms. Diagnosis could often be challenging due to their rarity. 18FDG-PET/CT had a high accuracy for poorly differentiated NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, Yang Z, Fan Y, Lu M, ...
Close
Notice
Important Notice:

In preparation of the upcoming 16th Annual ENETS Conference, 6 to 8 March 2019 in Barcelona, Spain, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2019 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.